The role of magnetic resonance imaging in prostate cancer patients on active surveillance
REFERENCES
1. . Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. Br J Radiol 2022; 95(1131):
20210842 . https://doi.org/10.1259/bjr.202108422. . Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 2019; 75: 712–20. doi: https://doi.org/10.1016/j.eururo.2018.11.031
3. . Longitudinal evaluation of apparent diffusion coefficient values as a predictor of prostate cancer research international active surveillance reclassification. Abdom Radiol (NY) 2022; 47: 814–26. https://doi.org/10.1007/s00261-021-03372-6
4. . Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597–603. doi: https://doi.org/10.1016/j.eururo.2012.11.005
REFERENCES
1. . Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. Br J Radiol 2022; 95(1131):
20210842 . doi: https://doi.org/10.1259/bjr.202108422. . Longitudinal evaluation of apparent diffusion coefficient values as a predictor of prostate cancer research international active surveillance reclassification. Abdom Radiol (NY) 2022; 47: 814–26. https://doi.org/10.1007/s00261-021-03372-6
3. . Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: A systematic review and meta-analysis. Eur Urol 2021; 80: 549–63:
S0302-2838(21)00325-0 . https://doi.org/10.1016/j.eururo.2021.05.0014. . MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 2021; 31: 2696–2705. doi: https://doi.org/10.1007/s00330-020-07336-0
5. . Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int 2019; 124: 758–67. doi: https://doi.org/10.1111/bju.14800
6. . Percent gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. [Internet]. Transl Androl Urol 2018; 7: S484–89. doi: https://doi.org/10.21037/tau.2018.03.20
7. . Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - A systematic review and meta analysis. BMC Cancer 2020; 20(1):
482 . https://doi.org/10.1186/s12885-020-06942-x8. . Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis. European Journal of Radiology 2019; 110: 22–29. https://doi.org/10.1016/j.ejrad.2018.11.014
9. . Hyperpolarised 13c-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer. Nat Commun 2022; 13(1):
466 . https://doi.org/10.1038/s41467-022-28069-210. . Quantitative prostate mri. J Magn Reson Imaging 2021; 53: 1632–45. doi: https://doi.org/10.1002/jmri.27191